What is MIP?
Welcome to the Medical Innovation Program (MIP) for Human Reproduction!
This program is an initiative by Merck KGaA, Darmstadt, Germany that supports early stage innovation in the field of Human Reproduction. The goal of MIP is to translate biomedical science into clinical applications for the benefit of patients by providing funding and support throughout the translation process.
To achieve this, the MIP operates through an externally-driven model of "Open Innovation" that supports co-development and collaboration, bringing together internal and external expertise. It serves as a platform for interdisciplinary, conceptual, theoretical and methodological debate on how to provide new solutions to boost innovation in reproductive medicine.
Why MIP?
Research findings are often not translated into novel therapies to exploit health gain in Human Reproduction. Many researchers work on wonderful innovative ideas of high potential for clinical application; however, they may be lacking the support and resources needed to successfully enter the development phase and finish the process of translation into products or services that benefit patients. The MIP aspires to bridge the gap between research and practice to bring innovative solutions from "bench to bedside".
Applicants may benefit from the online communication platform of MIP and interact with experts of various research and clinical backgrounds in a safe, intellectual property-protected environment.
Do you have a promising project and the aspiration to develop a product and bring it to the clinic? Then apply to the MIP!